Orlistat is a drug that was approved in early 1999 by the FDA (Food and Drug Administration) for use in weight reduction treatments up to 2 years.
As in the case of Sibutramine, Orlistat does not replace the diet, that is, any weight reduction treatment must be installed on the basis of dietoterápico treatment, increased activity physical and positive change in lifestyle. Not obtained the expected results, may be assessed the possibility of using these drugs without neglecting the above points.
Since orlistat works by reducing the absorption of fat consumed at each meal, does not justify the administration of drugs in foods that do not possess significant amounts of fat. Therefore it is recommended orlistat administration only during the course of lunch and dinner.
Also, you can skip taking orlistat when you eat a meal devoid of fat (eg, a lunch consisting of rice with grated carrot, no added oil) and resume treatment with the next meal (dinner).
Adverse effects
Adverse effects
systemic adverse effects attributable to orlistat were negligible. Patients should maintain a low fat intake to prevent or reduce these effects.
Because orlistat may decrease the absorption of fat soluble vitamins, recommended daily administration of common multivitamin supplements during the treatment period to prevent abnormalities in the serum concentration of vitamins. Fat-soluble vitamins should be administered at least two hours before or two hours after taking orlistat, it is recommended to do so before bedtime.
Based on the analyzed studies, orlistat is an effective drug for the treatment of obesity in patients who adhere to a hypocaloric diet and normograsa (30% VCT). Not addictive or produce a rebound effect. It should not be considered a "magic pill" that comes to supplant all known treatments. If it is not accompanied by proper diet tailored and supervised by a specialist, does not report any benefit.
